GenScript Biotech Corporation reports a stunning 27.3% revenue increase in H1 2026, driven by a surge in AI drug discovery services and strong performance across its business segments.

GenScript Biotech Corporation has unveiled its 2025 ESG Report, showcasing a paradigm shift in responsible biotech leadership. The company's commitment to sustainability is now a core part of its strategy.

Join scientific leaders and Nobel Laureates in London this November for insights into the future of cell and gene therapy, a game-changing field in medicine.

The GenScript Biotech Global Forum will feature Nobel Laureate Dr. Craig Mello and industry innovators tackling the future of cell and gene therapies.

GenScript Biotech Corporation gets upgraded to an AA ESG rating by MSCI, showcasing its commitment to sustainability and responsible practices globally.

GenScript Biotech has earned the prestigious EcoVadis Silver Medal, ranking in the top 15% globally for sustainability efforts, showcasing their commitment.

GenScript Biotech has unveiled its 2024 ESG report, detailing its continuous commitment to sustainability in environmental management, social responsibility, and corporate governance.

GenScript Biotech Corporation has been awarded the EcoVadis Bronze Medal for the second consecutive year, marking a strong commitment to sustainability in life sciences.

GenScript Biotech has entered a licensing agreement with the Broad Institute, enhancing its gene editing capabilities with prime editing technology.

GenScript Biotech Corp has received SBTi approval for its ambitious carbon emission reduction goals, paving the way towards a sustainable future that aligns with global climate efforts.

The 2025 JPM Global Forum by GenScript Biotech in San Francisco showcased significant advances in cell and gene therapy, gathering 700 attendees for insightful discussions.

GenScript Biotech Corporation introduces innovative packaging that greatly reduces waste and carbon emissions, supporting sustainability goals.